Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AGIX completes Phase IIb CAD enrollment

AtheroGenics (AGIX) completed enrollment of 500 coronary

Read the full 73 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE